Actualización del tratamiento de las hepatitis crónicas virales.

Norlan de la Cruz Alfonso, Rolando Martínez López

Texto completo:

PDF HTML

Resumen

Las consecuencias del daño hepático por los virus que producen lesiones crónicas constituyen un problema de salud mundial. Se realiza una revisión actualizada del tratamiento de las Hepatitis
crónicas por virus B, C y D, con referencia a trabajos publicados en la literatura especializada.

Palabras clave

Hepatitis crónica viral/terapia

Referencias

Malik AH, Lee WM. Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann Intern Med 2000; 132:723-31.

Valdés García L. Enfermedades emergentes y reemergentes. La Habana: Ministerio de Salud Pública; 1998.

Delgado González G, Galindo Sardiña MA, Pérez Blanco P. Hepatitis B en Cuba: década de los 90 y más allá del 2000. En: Centro de Ingeniería Genética y Biotecnología. Aplicaciones médicas de la biotecnología. Biotecnología Habana' 99; 1999 Nov 28 - Dic 3 La Habana. La Habana: Elfos Scientiae; 1999.pp.O20-O21.

Alter MJ. Epidemiology of hepatitis C. J Gastroenterol Hepatol 1996; 8:319-23.

Strader DB, Seeff LB. The natural history of chronic hepatitis C infection. J Gastroenterol Hepatol 1996; 8: 324-8.

Padrón GJ. Bases moleculares para el estudio de las hepatitis virales. La Habana: Elfos Scientiae; 1998.

Scully LJ. Treatment of chronic hepatitis B virus infection. Can J Gastroenterol 1997; 11:17- 20.

Di Bisceglie AM. Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J Hepatol 1995; 22:65-7.

Perrillo RP. Interferon therapy of chronic hepatitis B. En: Arroyo V, Bosh J, Rodes J, Eds. Treatments in hepatology. Barcelona: Masson; 1995.pp.141-53.

Perrillo RP. Chronic hepatitis B: problem patients (including patients with decompensated disease). J Hepatol 1995; 22:45-8.

Grob PJ. Hepatitis B:virus, pathogenesis and treatment. Vaccine 1998; 16:11-6.

Minuk YG. Principles in the management of chronic hepatitis B viral infection. (review) Can J Gastroenterol 1999; 13:75-7.

Nicoll A, Locarnini S. Present and future directions in the treatment of chronic hepatitis B infection. (review) J Gastroenterol Hepatol 1997; 12: 843-54.

Morrey JD, Korba BE, Sidwell RW. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection. Antivir Ther 1998; 3:59-68.

Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;

:1256-63.

Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a

randomised trial. Gut 2000; 46:526-8.

Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:61-8.

Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HB e/ HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32:300-6.

Malkan G, Cattral MS, Humar A, AL Asghar H, Greig PD, Hemming AW, et al. Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation 2000; 69:1403-7.

Rey D, Fritsch S, Schmitt C, Partisani M, Kempf-Durepaire G, Nicolle M, et al. Emergence of resistan hepatitis B virus strains during long-term lamivudine therapy in human

inmunodeficiency virus co-infected patients. Gastroenterol Clin Biol 2000; 24:125-7.

Petry W, Erhardt A, Heintges T, Haussinger D. New developments in therapy of chronic hepatitis B. When are nucleoside analogs indicated? Z Gastroenterol 2000; 38:77-87.

Renner EL. Hepatitis B: when to use lamivudine? Schweiz Med Wochenschr 2000; 130:39- 41.

Huo T-I, Wu J-C, Lin R-Y, Sheng W-Y, Chang F-Y, Lee S-D. Decreasing hepatitis D virus infection in Taiwan: An analysis of contributory factors. J Gastroenterol Hepatol 1997;

:747-51.

Farci P, Mandas A, Coiana A, Lai ME, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon alpha-2 a. N Engl J Med 1994; 330:88-94.

Van Leewen DJ, Dadrat A. Viral hepatitis and its imitators I: women's medicine. En: Blackwell RE, Ed. Cambridge: Blackwell Science; 1996.pp.324-38.

Carreño V, Bartolomé J, Madejón A. Hepatitis delta virus infection: molecular biology and treatment. Dig Dis 1994; 12:265-75.

González A, Esteban JI, Madoz P, Viladomiu L, Genesca J, Muñiz E, et al. Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: final report of a prospective trial. Hepatology 1995; 22:882-5.

National Institutes of Health. Chronic Hepatitis C: current disease management. New York: NIH; 2000 [Publication no 99-42 30].

National Institutes of Health. Consensus development conference: management of hepatitis C. Hepatology 1997; 26 (Suppl 1).

Spengler U, Rockstroh JK. Hepatitis C in the patient with human inmunodeficiency virus infection. J Hepatol 1998; 29: 1023-30.

Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa relapsers and non-responders: Italian experience. J Hepatol 1995; 23:13-6.

Schvarcz R, Ando Y, Sonnenborg A, Weiland O. Combination treatment with interferon alfa- 2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained

response to interferon alone: swedish experience. J Hepatol 1995; 23:8-12.

Lam NP. Hepatitis C: natural history, diagnosis and management. Am J Health-Syst Pharm 1999; 56:961-76.

Mc Hutchison JG, Gordon SC, Schiff ER. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. N Engl J Med 1998; 339:1485-92.

Lai MY. Firstline treatment for hepatitis C: combination interferon/ribavirin interferon monotherapy. J Gastroenterol Hepatol 2000; 15:130-3.

Olaso V, Córdoba J, Prieto M. Tratamiento de la hepatitis crónica C. Rev Esp Enf Dig 1997; 89:621-37.

Moscarella S, Buzzelli G, Romanelli RG, Monti M, Giannini C, Careccia G, et al. Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary

results. Liver 1998; 18:366-9.

Levine RA. Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time? Ann Intern Med 1998; 129:323-6.

Van Thiel DH, Friedlander L, Mallory P, Fagivoli S, Wright HI, Gasbarrin A, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and

withaut phlebotomy. Gastroenterology 1994; 106:1002.

Arús Soler E. Estado actual del tratamiento de las hepatitis virales crónicas. Jornadas LUSO-Cubanas de Gastrenterologia em Medicina Geral e Familiar; 2000 Jul 21-26; Varadero. Lisboa: Faculdade de Ciencias Médicas de Lisboa; 2000.pp.36-39.

Kobayashi M, Chayama K, Arase Y, Tsubota A, Saitoh S, Susuki Y, et al. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with

interferon a. J Gastroenterol 1999; 34:94-9.

Gish GR. Future directions in the treatment of patients with chronic hepatitis C virus infection. Can J Gastroenterol 1999; 13:57-62.

Enlaces refback

  • No hay ningún enlace refback.


Copyright (c) 2020 Norlan de la Cruz Alfonso, Rolando Martínez López

Licencia de Creative Commons
Este obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.